

Review Article

Staunch the Age Related Decline into Dementia, Cancer, Autoimmunity (Long Covid), Obesity, and Other Diseases with a Prebiotic, Probiotic, Postbiotic Triple Play

Patrick Chambers¹

1. Dept of Pathology, Torrance Memorial Medical Center, Torrance, United States

“All diseases originate in the gut.” Hippocrates (400 BC)

A healthy gut microbiome via the gut-brain-axis elevates heart rate variability (HRV), a general measure of health and well-being. A dysbiotic gut microbiome, low in biodiversity and butyrate producers, can alter tryptophan metabolism (ATM) and increase the kynurenine to tryptophan ratio (KTR) with release of proinflammatory cytokines, predominantly TNF- α , IL-6, and IL-1 β . These also characterize chronic inflammation, oxidative stress, and a multitude of diseases. Also proposed is the gut-lung dysbiosis concept and consequent degradation of ACE2 (richest in lungs and gut). Leaky gut (and lung) induced autoantibodies (AAs) related to G-protein coupled receptors (GPCRs) in combination with increased Ang II further potentiate oxidative stress. The underappreciated pathogenic role of Candida is explored. The efficacy of fecal microbiome transplantation (FMT) in treating dementia, cancer, and autoimmunity supports the plausibility of success with “FMT-lite”. This triple play of prebiotic (d-mannose), probiotic (bifidobacteria and lactobacilli), and postbiotic (butyrate) might improve intestinal barrier integrity, oppose entry of GPCR antigens, suppress the inflammatory cytokine triad, balance IFN- γ and TGF- β , suppress oxidative stress, depress KTR, elevate HRV, and extend lifespan and its quality.

Corresponding author: Patrick Chambers, pwc@gte.net

Hypothesis

1. Gut dysbiosis (and SARS CoV2) depresses ACE2, vital to intestinal barrier integrity and tryptophan absorption
2. Tryptophan and vitamin D deficiencies promote pathogenic hyphal transition of commensal Candida yeast forms
3. Estrogen facilitates immune evasion by Candida
4. Invasive Candida hyphae are rich in surface GPCRs (only present on eukaryotes) and can trigger GPCR AAs
5. LC symptoms are primarily due to GPCR AAs (~800 different candidates in humans)
6. Candida elicits a robust IFN- γ response that drives ATM and females produce a more robust IFN- γ response
7. ATM upregulates IDO, linked to dementia and autoimmunity in females (IFN- γ) and cancer/organ fibrosis in males (TGF- β)
8. TGF- β (reciprocal cytokine to IFN- γ) regulates tolerogenesis; too little, self antigens targeted, too much, tumor antigens not targeted
9. D-mannose enhances intestinal barrier integrity and butyrate immuno-modulates IFN- γ , TGF- β
10. Candida potentiates gut dysbiosis and is a major player in determining long term health

1. Introduction

Pursuit of a healthier and happier lifestyle is a universal goal.

Better diet and more exercise are at the top of New Year's resolutions. But eating favorite foods is one of the great joys in life and exercise, not so much. Balance is the key to achieving these goals, whether it be between the opposing enzymes ACE and ACE2 or the pleiotropic cytokines IFN- γ and TGF- β . However, several supplements readily available may assist in this pursuit of balance.

Although this article cites an abundance of recent research supporting its content, it is speculative and the inferences are in part theoretical. It attempts to connect pleiotropic cytokines, gut dysbiosis, GPCR AAs, and disease with oxidative stress under the HRV umbrella (see Figure 1). Prebiotic d-mannose (a dietary fiber substitute), a probiotic rich in bifidobacteria and lactobacilli, and postbiotic butyrate (best short chain fatty acid or SCFA) are proposed as partial solutions. HRV, a function of beat to beat interval,

is proposed as a monitor of efficacy. It is the “fifth vital sign” and is more comprehensive and predictive in its assessment than those of the four traditional vital signs.




Figure 1. Pathways to a healthy HRV and enhanced lifespan are demonstrated. The Western Lifestyle includes an increased calcium to magnesium ratio, vitamin D deficiency, decreased antioxidants, toxins, e.g., smoking. $\text{TNF-}\alpha$, IL-6, IL-1 β comprise the triad. The trigger for the pleiotropic switch is not yet clear. Biologic individuality is also a prime determinant of differential pathway traffic.

2. Oxidative Stress and Gut Dysbiosis

Aging reflects the accumulated damage over a lifetime wrought by oxidative stress. This stress arises when energy needs increase and reactive oxygen species (ROS) generated within mitochondria remain unquenched due to insufficient onboard antioxidants. Psychological stress induces oxidative stress by increasing circulating cortisol and norepinephrine, which generate mitochondrial ROS^[1]. Mental stress is

also linked with gut dysbiosis^[2], which upregulates oxidative stress^[3]. Excess ROS compromise mitochondrial efficiency and gut microbial diversity. Gut microbes themselves impact ROS generation.

Gut dysbiosis occurs when the gut microbiome is unbalanced, i.e., gut microbiota are not diverse and SCFA producing bacteria are in short supply. SCFAs are the end products of fermentation of dietary fibers by anaerobic intestinal bacteria and exert multiple beneficial effects on energy metabolism^[4].

They are the primary energy substrate for colonic epithelial cells. Propionate and butyrate comprise 25% and 15% respectively of these SCFAs^[5]. Acetate, which comprises ~60%, promotes obesity by stimulating insulin secretion and hyperphagia^{[6][7]}. Propionate and butyrate stimulate secretion of insulin and glucagon-like peptide 1 (GLP-1), which suppresses appetite^{[8][9]}. Ozempic is a GLP-1 agonist. On the other hand, oxidative stress enhances acetate dependent lipogenesis, i.e., promotes obesity^[10]. Excess weight gain and obesity are features of Covid-19 and LC, which share the same gut microbiome, low in butyrates. Persistent low grade oxidative stress is tightly linked to excitatory glutamate neurotransmission^[11]. Glutamate producing gut bacteria outperform their butyrate/ γ -amino butyric acid producing counterparts and create an imbalance in excitatory and inhibitory neurotransmission in the autonomic nervous system^[12].

3. ATM and KTR

Tryptophan, an essential amino acid, from diet or synthesized by intestinal bacteria can follow one of three major metabolic pathways: 1) intestinal bacterial indole synthesis, 2) the kynurenine pathway in immune and epithelial cells (95% of tryptophan), or 3) the serotonin pathway (90% of total body serotonin) in enteroendocrine aka enterochromaffin cells and initiation of vagal afferent signals^[13]. During ATM tryptophan pivots away from the serotonin pathway and synthesis of serotonin and melatonin to the kynurenine pathway (see Figure 2). Inhibitory parasympathetic signals are suppressed due to the increase in excitatory glutamate activity. This pivot down-regulates bacterial indole synthesis with loss of indole induced GLP-1. Benefits of GLP-1 include appetite suppression, stimulation of insulin^[14], decrease in fasting blood sugar^[15], suppression of obesity and T2DM^[16]. Many of the same bacteria that produce SCFAs, e.g., bifidobacteria and lactobacilli, also synthesize indoles from tryptophan^[17]. Although the end product NAD⁺ (see Figure 2) assists dysfunctional mitochondria in ATP production, what drives the ATM pivot is not clear. However, IFN- γ , upregulated in females, is a cofactor for many enzymes in the kynurenine pathway and may drive this pivot^[18] (see Figure 2). Tryptophan

depletion lowers HRV (and increases KTR)^[19]. Increased tryptophan intake (eggs) increases HRV, which appears to be due to the subsequent increase in serotonin^[20]. KTR, an indicator of rate-limiting IDO activity, is positively correlated with cardiovascular disease mortality^{[21][22]}, depression, bipolar disorder, schizophrenia,^[23] Alzheimer's disease, fronto-temporal dementia,^[24] Parkinson's disease^[25], and neurological disease in general^[26]. Increased KTR has also been reported in cancer^[27], autoimmune disease, including rheumatoid arthritis (RA)^[28], and systemic lupus erythematosus (SLE)^[29]. Infectious diseases are also linked to an elevated KTR^[30] with a ratio that directly reflects severity^{[31][32]}. This includes SARS CoV2^[33]. SARS CoV2 induced loss of ACE2 receptor bearing intestinal epithelial cells depresses absorption of the essential amino acid tryptophan^[34] and depressed tryptophan levels promote yeast-to-hyphal transition^[35].




Figure 2. Altered tryptophan metabolism is demonstrated. NMDA-R=N-methyl-D-aspartate receptor is an excitatory glutamate receptor. Note the upregulating presence of the proinflammatory cytokine IFN-γ^{[36][23]}
^[37].

4. IFN- γ and TGF- β

IFN- γ and TGF- β are polarizing cytokines (reciprocal relationship)^[38] and counterbalance each other^[39]. IFN- γ is pro-inflammatory and TGF- β is anti-inflammatory. When an imbalance arises, autoimmune disease/IFN- γ and cancer/TGF- β , two immunological opposites^[40], can develop. These counterbalancing cytokines are in turn immuno-modulated by the gut microbiome. This is demonstrated by the utility of FMT in cancer^[41], autoimmune disease^[42], and dementia^[43].

Reports on the efficacy of FMT for obesity are mixed. However, they include no concomitant prebiotic. Whether the microbiome is upgraded via probiotics or FMT, failure to simultaneously upgrade the diet or otherwise provide sustenance to the new microbiota compromises efficacy. Also, the postbiotic butyrate stimulates release of GLP-1^{[8][9]}. The highly popular weight loss drug Ozempic (semaglutide) is a GLP-1 agonist. Elevated IFN- γ characterizes parasitic infestations. In such patients this cytokine was positively associated with a good prognosis in Covid-19^[44]. Low baseline IFN- γ response could predict hospitalization^[45] and post discharge fibrosis in COVID-19 patients^[43]. On the other hand its reciprocal, TGF- β , was positively associated with Covid-19 severity^[46] and fibrosis^[47]. Even outside the TME TGF- β promotes fibrosis, counterbalanced by IFN- γ . These cytokines are directly linked to the KTR and IDO. IDO, the enzyme, works to restrain excessive or inappropriate immune activation in the TME^[48]

However, IDO is not only an enzyme induced by IFN- γ (increased KTR) but also an intracellular signal transducer induced by TGF- β (TME)^{[49][50][51]}

Pleiotropism is the expression of different traits by the same gene. IFN- γ can pivot from pro-inflammatory and anti-proliferative to tumor promoter and TGF- β can pivot from tumor suppressor to tumor promoter. What triggers the pleiotropic switch from tumor suppressor to tumor promoter for either IFN- γ or TGF- β is not clear, but may be related to the TME milieu, where TGF- β appears to dominate^[52]. In an imbalanced (elevated TGF- β /IFN- γ) TGF- β may trigger fibrosis and the TME via paracrine transmission. IFN- γ is generally considered pro-inflammatory but anti-proliferative. But in the TME it can induce programmed cell death protein-1 (PD-1) expression linked to metastasis (see Figure 3)^[53]. TGF- β is generally considered anti inflammatory and a tumor suppressor, but in the TME it becomes a tumor promoter, triggering cancer associated fibroblasts (CAF), epithelial/endothelial mesenchymal transformation (EMT), and vascular endothelial growth factor (VEGF), possibly mediated by methylation of its epigenome. The switch seems to occur in the TME. The relative concentrations of IFN- γ and TGF-

β ^[54] or local hypoxia^[55] may instigate this. Interestingly tumors treated with low-dose IFN- γ acquired metastatic properties while tumors infused with high dose IFN- γ regressed^[54].

Perhaps TGF- β concentration in the TME can trigger a pleiotropic switch in low dose IFN- γ but at a higher dose IFN- γ can modulate its reciprocal in the TME. Cancer cells can also produce TGF- β . Pleiotropic IFN- γ is linked with metastatic behavior via upregulation of PD-1^[56]. Angiotensin II stimulates the TGF- β signaling pathway^[57]. This may in part explain the predilection for and severity of Covid-19 in males with comorbidities and for recurrent cancer in those previously in remission (see Figure 3). On the other hand, females are robust producers of type I interferon^[58]. Type 1 IFNs (IFN- α and IFN- β) are first responders to any invading pathogen and trigger release of interferon-stimulated genes for synthesis of IFN- γ .

Its reciprocal, TGF- β , is vital to the maintenance of tolerogenesis and avoidance of autoimmunity. If TGF- β /IFN- γ is low, self recognition and tolerance may be compromised (autoimmunity)^[59]. If TGF- β /IFN- γ is high, tumor associated antigens may be tolerated (cancer)^[60]. An increased TGF- β /IFN- γ is also a risk factor for tissue fibrosis^{[61][62][63]}.




Figure 3. Proposed flow chart leading to cancer, demonstrating behavior of the cytokines TGF- β and IFN- γ in the tumor microenvironment (TME) that pleiotropically pivot from anti-inflammatory/tumor suppressor to tumor promoter (TGF- β) and from pro-inflammatory/tumor suppressor to tumor promoter (IFN- γ).

TME=tumor microenvironment, CAF=cancer associated fibroblast, VEGF=vascular endothelial growth factor, EMT=epithelial or endothelial mesenchymal transformation, PD=programmed cell death protein-1, ERK=extracellular signal regulated kinase, IDO=indoleamine 2,3-dioxygenase. Figure 3 complements Figure 2.

5. GPCR

A. GPCR and SARS CoV-2

Recent research, including a 2023 international symposium, has focused on AAs targeting G-protein coupled receptors^[64]. Their roles in Covid-19^[65] and LC have been reported^[66]. More than 800 different GPCRs have been identified, as of 2020^[67]. In one study a majority of those with POTS possessed adrenergic and muscarinic cholinergic receptor AAs. These are all G-protein coupled receptors, as is AT1R. Antibodies to these receptors are also associated with chronic fatigue syndrome (CFS), fibromyalgia (FM), Covid, LC^{[68],[69]} and with other autoimmune diseases (including SLE, RA, Crohn's disease^[70]). Many of these did poorly during the pandemic^[71]. POTS or POTS-like symptoms develop in 10-50% of long haulers, yet there are significant hormonal differences, e.g., low cortisol in LC^[72] but high cortisol in POTS^{[73],[74]}. In POTS the adrenals respond to ACTH^[75], but in LC they do not and symptoms can mimic adrenal insufficiency. ACTH receptors are GPCRs and AAs might inactivate receptors, as GPCR antibodies can activate or inactivate^[76]. POTS is easily diagnosed and pathogenesis points to the baroreflex and the neurohypophysis (see Figure 4). The wealth of GPCRs in the involved CNS nuclei^[77] and the link between GPCRs and autoimmunity underscore the probable GPCR induced autoimmune pathogenesis for LC.

Covid-19 may be due to AAs to GPCR bearing platelets^{[85][86]} or phospholipids^[87], perhaps reflecting some degree of gut dysbiosis. AAs were present in 50% of those with Covid-19 versus only 15% in healthy controls^[88].

B. GPCR and Gut Dysbiosis

The gut-lung axis is based on the concept of continuity between their microbiota forming a microbial community^{[89][90]}. Cutaneous, nasopharyngeal, and vaginal microbiomes are members of this community. ACE2 receptors are highest in lung and GI tract^[91], primary targets for SARS CoV2. But ACE2 is more than just an enzyme. It is negatively associated with gut dysbiosis^[92] and positively associated with tryptophan absorption^[34].

G-protein-coupled receptors (GPCRs) are the largest class of cell surface receptors in fungi^[93] and *Candida* is tightly linked to gut dysbiosis and LC^[94]. Tryptophan^[35] and vitamin D^[95] inhibit the commensal yeast to pathogenic hyphae transition. GPCRs induce transition of commensal yeast forms to pathogenic hyphal forms^[96] and are required for *Candida* biofilm formation^[97]. Hyphal cell walls are rich in GPCRs^[98] that may breach the intestinal barrier and trigger production of anti-GPCR AAs. Surprisingly estrogen promotes innate immune evasion of *Candida albicans* through inactivation of the alternative complement system^[99]. *Candida* and SARS CoV2 may conspire in this process. SARS CoV2 can initiate not only gut dysbiosis through loss of ACE2 bearing intestinal epithelial cells but also LC symptoms through GPCR AAs induced by *Candida* associated gut dysbiosis (see Figure 4). This may also occur in the lungs of ARDS patients, where both invasive *Candida*^[100] and GPCR antibody mediated lung edema^[101] have been reported. Although cell wall/membrane surface GPCRs are only present on eukaryotes, i.e., not on viruses or bacteria, SARS CoV2 appears to be a ligand for some GPCRs^{[102][103]}, especially those in the brain^[104], e.g., NMDA-Rs (see Figure 2) that control taste, smell, and baroreflex and symptoms like brain fog and fatigue^[105]. As a ligand, SARS CoV2 can disrupt GPCR signaling^[106]. GPCR signaling can also be disrupted by AAs. Why do GPCR AAs figure so prominently and what is prompting the TGB- β /IFN- γ imbalance? Animals infected with SARS CoV2 generate GPCR AAs to the same AT1Rs, β 2 adrenergic and muscarinic receptors encountered in LC^[107]. Furthermore, the receptors most frequently targeted by AAs in LC^[108] are at least partially regulated by GPCRs - autoimmune thyroiditis (Graves disease, Hashimoto's thyroiditis)^{[109][110]}, celiac disease^{[111][112]}, inflammatory bowel disease^[113], myasthenia gravis^[114], pernicious anemia^[115], psoriasis^[116], RA^[117], Sjogren's syndrome^[118], SLE^[119],

type 1 diabetes mellitus (T1DM)^[120], and vitiligo^[121]. Many of these autoimmune diseases have been escalating for decades before the pandemic (see figure 5). SARS CoV2 induced loss of ACE2 bearing cells and associated gut dysbiosis may have accelerated this. For many of these autoimmune diseases similar gut microbiomes and concomitant Candida overgrowth have been reported. The linkages are clear and the notion of causation (Candida) is provocative.




Figure 5. From: Bach, JF, The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases, NEJM 347(12):911-920.

SARS CoV2 may trigger AAs to GPCRs even in the absence of severe disease^[107]. GPCR AAs are associated with dysautonomia and post viral fatigue disorders^[70]. Pre-existing gut dysbiosis, e.g., *Candida* overgrowth after antibiotics, enhanced by a GPCR related viral assault like SARS CoV2 or HIV^[122] may trigger or worsen symptomatic expression, e.g., dysautonomia^[123].

But females exhibit more robust T cell activation than males^[124] and produce higher levels of interferon^[125], predisposing autoimmunity (see Figure 2). Fungal infections, especially *Candida*, elicit a robust IFN- γ response^{[126][127]} and drive the serotonin to kynurenine pathway pivot (see Figure 2). New onset T2DM has been reported post Covid-19^[128]. Pancreatic β -cells have numerous GPCRs that can activate or inhibit β -cell insulin secretion^[129]. Several autoimmune skin diseases have also been reported post Covid-19. These include alopecia areata in addition to psoriasis, and vitiligo. G-protein coupled receptors stimulate hair follicle stem cells and promote activation of the hair cycle^[130]. GPCR activity is decreased in psoriatic skin and can be alleviated by topical butyrate^{[131][132]}. Not surprisingly, cutaneous *Candida* colonization is linked to psoriasis^[133]. GPCRs that augment melanocyte growth are depressed in Covid-19/LC induced vitiligo^[134].

GPCR autoantibody induced upregulation of AT1R activity also activates JAK/STAT pathways^[135]. JAK/STAT pathways are strongly linked to cancer, autoimmunity, and dementia. Cytokine receptors targeted by JAK/STAT signaling are GPCRs^[136] and can be activated by AAs^[76]. The role of GPCRs in driving cancer has been acknowledged but remains unexplained. Perhaps the gut microbiome might provide answers^[137]. JAK inhibitors are very popular in the treatment of autoimmune disease, cancer and dementia, all linked to the inflammatory triad of TGF- β , IL-6, IL-1 β . Interestingly subclinical AAs autoantibodies to GPCR can be present in otherwise healthy individuals^[2].

6. HRV and the Triple Play

A. HRV

The cytokine triad of TNF- α ^{[7][138][139]}, IL-6^{[79][140]}, and IL-1 β ^[79] are negatively linked to HRV and positively linked to CRP^[65]. Cancer diagnosis and prognosis are linked to TNF- α ^[141], IL-1 β ^{[142][143]}, and IL-6. Low HRV can alert one to asymptomatic infection and inflammation^{[144][145]}, anxiety^[146], depression^{[147][148]}, cognition and neurodegenerative disorders^{[149][150]}, psychosis spectrum disorders^[151], cancer^{[152][153]}, cardiovascular disease^{[154][155]}, stroke^{[156][157]}, T2DM^{[158][159]}, severe Covid-

19^[160], Long Covid^{[161][162][163]}, MS^[164], SLE^[165], and RA^[166]. Central aka visceral adiposity (waist hip ratio, waist circumference) is negatively related to HRV and a much more sensitive indicator than BMI^[167]^{[168][169]}. Peripheral obesity is not only not associated with a low HRV but is protective with elevated HRV^[170].

B. Triple Play

Butyrate enhances mitochondrial function during oxidative stress^[171] and rescues tryptophan^[172]. Serotonin cannot cross the BBB, but tryptophan can, and by rescuing tryptophan, butyrate can increase brain serotonin (inhibitory neurotransmitter). Butyrate also suppresses IDO activity^[173] and immunomodulates IFN- γ and TGF- β ^[174]. Butyrate producing gut microbiota^[175], gut biodiversity, and production of SCFAs^[176] are associated with elevated HRV. Unfortunately butyrate producing Bacteroidetes species decline with age^[177]. Butyrate alleviates obesity and related comorbidities^{[178][179][180]}. But not all SCFAs have beneficial effects on human health. Acetate not only promotes obesity^{[7][181]} but can also be used by tumor cells as an energy substrate during oxidative stress^[182]. Postbiotic butyrate bypasses the negative effects^[6] of Bacteroides produced acetate^[183].

Prebiotic D-mannose assists dietary fiber in propagating butyrate producers^[184]. It enhances intestinal barrier integrity^[185] and opposes the proinflammatory effects of glucose and fructose^[186]. D-mannose opposes diet induced obesity^[187], positively associated with CRP and negatively associated with HRV^[188]. Central adiposity is adverse and linked to elevated CRP, while peripheral adiposity is favorable and not so linked^{[189][190]}. D-mannose not only downregulates gut dysbiosis by enhancing intestinal barrier integrity^{[184][185]} but also suppresses the adipokine and cytokine triad (TNF- α , IL-6, IL-1 β)^{[191][192][193]}, linked to cancer^{[194][195]}, cardiovascular disease^[196], stroke^[197], obesity^[198], diabetes^[199], neurodegenerative disease^[200], and autoimmune disease^{[201][202]}. D-mannose suppresses autoimmune diseases, e.g., T1DM, asthma, and SLE^[203] by suppressing IFN- γ ^{[39][148]}. D-mannose can suppress ERK (extracellular signal regulated kinase) signaling pathways (see Figure 3)^[204] integral to TGF- β induced organ fibrosis^[205], transformation of fibroblasts into CAFs^[206], epithelial/endothelial mesenchymal transformation (EMT)^[207], and VEGF synthesis^[208]. D-mannose inhibits PD-1 (see Figure 3)^[209], upregulated in Covid-19^[210]. This pathway to tumorigenesis is separate but complementary to that induced by TGF- β ^[211] (see Figure 3). Probiotics also increase HRV and have proven efficacious in LC^[212]^[81]. Probiotics and antioxidants are nutraceuticals that have proven most effective in Covid-19 and LC^[213].

Prebiotic is more important than postbiotic, as SCFA producing bacteria cannot flourish without dietary fiber or its equivalent (d-mannose).

7. Conclusion

Gut (and lung) dysbiosis and Candida overgrowth induced GPCR AAs may be at the root of the vast majority of our health problems, including cancer, dementia, autoimmunity, obesity, post viral fatigue syndrome (LC, CFS, FM, Epstein Barr Virus), and many infectious diseases. A gut leaking Candida hyphae laden with GPCRs stimulates production of host AAs that activate AT1Rs, adrenergic, and mucarinic receptors, and many others at the heart of many comorbidities.

The growing epidemic of LC has spawned tremendous suffering and economic loss. The bidirectional correlations between gut dysbiosis and inflammatory cytokines, disease, and HRV/KTR/CRP make supplementation the most feasible path to better health. This triple play of prebiotic d-mannose, a probiotic of diverse butyrate producing bacteria, and postbiotic butyrate can provide a strong assist. Limit inflammaging and oxidative stress (see Figures 1,4) and embrace antioxidants to maintain mitochondrial health.

Adding exercise to this regimen further energizes HRV^[214]. Monitoring a rising HRV and possibly a falling waistline^{[167][168]} due to butyrate^[9] and indole^{[14][15][16]} induced GLP-1 can provide positive feedback and boost incentive during the effort. This approach affords the individual an inexpensive and convenient path to a more healthful existence without necessarily forcing dietary and other lifestyle changes. Changing ones diet may be more difficult than changing ones religion.

Obtaining an accurate HRV via bluetooth enabled chest strap, armband, finger sensor, or wristwatch can be tedious, but HRV is especially useful in following the benefits of dietary changes,^[215] and significant benefits to a more healthful lifestyle and lifespan^[216] await.

Although the ideas proposed in this review are in part speculative and underscore associations, they do not prove causation. That remains for randomized controlled trials.

“Death sits in the bowel.” Hippocrates (400 BC)

Other References

- Wendell SG, Fan H, Zhang C. G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. *Pharmacol Rev.* 2020 Jan;72(1):1-49. <https://doi.org/10.1124/pr.118.016899>

References

1. ^aFlaherty RL, Owen M, Fagan-Murphy A, Intabli H, Healy D, Patel A, et al. Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer. *Breast Cancer Res.* 2017 Mar 24;19(1):35. <https://doi.org/10.1186/s13058-017-0823-8>
2. ^aYang HL, Li MM, Zhou MF, Xu HS, Huan F, Liu N, et al. Links Between Gut Dysbiosis and Neurotransmitter Disturbance in Chronic Restraint Stress-Induced Depressive Behaviours: the Role of Inflammation. *Inflammation.* 2021 Dec;44(6):2448-2462. <https://doi.org/10.1007/s10753-021-01514-y>
3. ^aShandilya S, Kumar S, Kumar Jha N, Kumar Kesari K, Ruokolainen J. Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection. *J Adv Res.* 2021 Sep 17;38:223-244. <https://doi.org/10.1016/j.jare.2021.09.005>
4. ^aden Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res.* 2013 Sep;54(9):325-40. <https://doi.org/10.1194/jlr.R036012>
5. ^aLiu H, Wang J, He T, Becker S, Zhang G, Li D, Ma X. Butyrate: A Double-Edged Sword for Health? *Adv Nutr.* 2018 Jan 1;9(1):21-29. <https://doi.org/10.1093/advances/nmx009>
6. ^aRidler, C. Acetate promotes obesity via a gut-brain- β -cell axis. *Nat Rev Endocrinol* 12, 436 (2016). <https://doi.org/10.1038/nrendo.2016.93>
7. ^aLin HV, Frassetto A, Kowalik Jr EJ, Nawrocki AR, Lu MM, Kosinski JR, et al. (2012) Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms. *PLoS ONE* 7(4): e35240. <https://doi.org/10.1371/journal.pone.0035240>
8. ^aPsichas, A., Sleeth, M., Murphy, K. et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. *Int J Obes* 39, 424-429 (2015). <https://doi.org/10.1038/ijo.2014.153>
9. ^aYadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. *J Biol Chem.* 2013 Aug 30;288(35):25088-25097. <https://doi.org/10.1074/jbc.M113.452516>

10. [△]Bose S, Ramesh V, Locasale JW. Acetate Metabolism in Physiology, Cancer, and Beyond. *Trends Cell Biol.* 2019 Sep;29(9):695-703. <https://doi.org/10.1016%2Fj.tcb.2019.05.005>
11. [△]Grignon, S., & Deslauriers, J. (2015). The Reciprocal Effects of Oxidative Stress and Glutamate Neurotransmission. *Medicine, Biology* https://doi.org/10.1007/978-1-4939-0440-2_11
12. [△]Baj A, Moro E, Bistoletti M, Orlandi V, Crema F, Giaroni C. Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis. *Int J Mol Sci.* 2019 Mar 25;20(6):1482. <https://doi.org/10.3390/ijms20061482>
13. [△]Benech N, Rolhion N, Sokol H. Tryptophan metabolites get the gut moving. *Cell Host Microbe.* 2021 Feb 10; 29(2):145-147. <https://doi.org/10.1016/j.chom.2021.01.009>
14. [△]Roager, H.M., Licht, T.R. Microbial tryptophan catabolites in health and disease. *Nat Commun* 9, 3294 (2018). <https://doi.org/10.1038/s41467-018-05470-4>
15. [△]Zhou Y, Chen Y, He H, Peng M, Zeng M, Sun H. The role of the indoles in microbiota-gut-brain axis and potential therapeutic targets: A focus on human neurological and neuropsychiatric diseases. *Neuropharmacology.* 2023 Nov 15;239:109690. <https://doi.org/10.1016/j.neuropharm.2023.109690>
16. [△]Liu JJ, Ching J, Wee HN, Liu S, Gurung RL, Lee J, et al, Subramaniam T, Sum CF, Sharma K, Kestenbaum B R, Lim SC. Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. *Diabetes Care.* 2023 Dec 1;46(12):2223-2231. <https://doi.org/10.2337/dc23-1147>
17. [△]Ye X, Li H, Anjum K, Zhong X, Miao S, Zheng G, Liu W, Li L. Dual Role of Indoles Derived From Intestinal Microbiota on Human Health. *Front Immunol.* 2022 Jun 17;13:903526. <https://doi.org/10.3389%2Ffimmu.2022.903526>
18. [△]Gietl M, Burkert F, Seiwald S, Böhm A, Hofer S, Gostner JM, et al. Interferon-gamma Mediated Metabolic Pathways in Hospitalized Patients During Acute and Reconvalescent COVID-19. *Int J Tryptophan Res.* 2023 Feb 13;16:11786469231154244. <https://doi.org/10.1177/11786469231154244>
19. [△]Booij, L., Swenne, C.A., Brosschot, J.F., Haffmans, P.M., Thayer, J.F., & van der Does, A.J. (2006). Tryptophan Depletion Affects Heart Rate Variability and Impulsivity in Remitted Depressed Patients with a History of Suicidal Ideation. *Biological Psychiatry*, 60, 507-514. <https://doi.org/10.1016/j.biopsych.2006.02.010>
20. [△]Zahar S, Schneider N, Makwana A, Chapman S, Cortes J, Amico M, et al. Dietary tryptophan-rich protein hydrolysate can acutely impact physiological and psychological measures of mood and stress in healthy adults. *Nutr Neurosci.* 2023 Apr;26(4):303-312. <https://doi.org/10.1080/1028415X.2022.2047435>
21. [△]Gáspár R, Halmi D, Demján V, Berkecz R, Pipicz M, Csont T. Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease. *Front Immunol.* 2022 Feb 8;12:768560. <https://doi.org/10.33>

22. ^ΔLund A, Nordrehaug JE, Slettom G, Solvang SH, Pedersen EK, Midttun Ø, et al. Plasma kynurenines and prognosis in patients with heart failure. *PLoS One*. 2020 Jan 10;15(1):e0227365. <https://doi.org/10.1371/journal.pone.0227365>
23. ^Δ^bMarx, W, McGuinness, A.J., Rocks, T. et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. *Mol Psychiatry* 26, 4158–4178 (2021). <https://doi.org/10.1038/s41380-020-00951-9>
24. ^ΔHeylen A, Vermeiren Y, Kema IP, van Faassen M, van der Ley C, Van Dam D, et al. Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. *Pharmaceuticals*. 2023; 16(4):615. <https://doi.org/10.3390/ph1604061>
25. ^ΔChen P, Geng X. Research progress on the kynurenine pathway in the prevention and treatment of Parkinson's disease. *J Enzyme Inhib Med Chem*. 2023 Dec;38(1):2225800. <https://doi.org/10.1080/14756366.2023.2225800>
26. ^ΔLovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. *Neuropharmacology*. 2017 Jan;112(Pt B):373–388. <https://doi.org/10.1016/j.neuropharm.2016.03.024>
27. ^ΔAla M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. *Eur J Pharmacol*. 2021 Apr 5;896:173921. <https://doi.org/10.1016/j.ejphar.2021.173921>
28. ^ΔMangoni AA, Zinellu A. A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases. *Front Immunol*. 2023 Oct 23;14:1257159. <https://doi.org/10.3389/fimmu.2023.1257159>
29. ^ΔEryavuz Onmaz, D., Tezcan, D., Yilmaz, S. et al. Altered kynurenine pathway metabolism and association with disease activity in patients with systemic lupus. *Amino Acids* 55, 1937–1947 (2023). <https://doi.org/10.1007/s00726-023-03353-7>
30. ^ΔEller, S.K., Däubener, W. (2015). Role of Kynurenine Pathway in Infections. In: Mittal, S. (eds) *Targeting the Broadly Pathogenic Kynurenine Pathway*. Springer, Cham. https://doi.org/10.1007/978-3-319-11870-3_14
31. ^ΔDarcy CJ, Davis JS, Woodberry T, McNeil YR, Stephens DP, Yeo TW, Anstey NM. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. *PLoS One*. 2011;6(6):e21185 <https://doi.org/10.1371/journal.pone.0021185>
32. ^ΔFadhilah F, Indrati AR, Dewi S, Santoso P. The Kynurenine/Tryptophan Ratio as a Promising Metabolomic Biomarker for Diagnosing the Spectrum of Tuberculosis Infection and Disease. *Int J Gen Med*. 2023 Nov 28;1

6:5587-5595. <https://doi.org/10.2147%2FIJGM.S438364>

33. [△]Lionetto L, Ulivieri M, Capi M, De Bernardini D, Fazio F, Petrucca A, et al. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. *Biochim Biophys Acta Mol Basis Dis*. 2021 Mar 1;1867(3):166042. <https://doi.org/10.1016/j.bbadis.2020.166042>
34. [△]Jin B, Singh R, Ha SE, Zogg H, Park PJ, Ro S. Pathophysiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19. *World J Gastroenterol*. 2021 May 21;27(19):2341-2352. <https://doi.org/10.3748%2Fwjg.v27.i19.2341>
35. [△]Bozza S, Fallarino F, Pitzurra L, Zelante T, Montagnoli C, Bellocchio S, et al; A Crucial Role for Tryptophan Catabolism at the Host/*Candida albicans* Interface. *J Immunol* 1 March 2005; 174 (5): 2910–2918. <https://doi.org/10.4049/jimmunol.174.5.2910>
36. [△]Croitoru-Lamoury J, Lamoury FMJ, Caristo M, Suzuki K, Walker D, Takikawa O, et al. (2011) Interferon- γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO). *PLoS ONE* 6(2): e14698. <https://doi.org/10.1371/journal.pone.0014698>
37. [△]Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, et al. Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study. *Alzheimers Dement*. 2017 Dec;13(12):1327-1336. <https://doi.org/10.1016/j.jalz.2017.04.009>
38. [△]Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M. Reciprocal IFN- γ and TG F- β responses regulate the occurrence of mucosal inflammation. *Immunol Today*. 1997 Feb;18(2):61-4. [https://doi.org/10.1016/s0167-5699\(97\)01000-1](https://doi.org/10.1016/s0167-5699(97)01000-1)
39. [△]Gauthier T, Chen W. IFN- γ and TGF- β , Crucial Players in Immune Responses: A Tribute to Howard Young. *J Interferon Cytokine Res*. 2022 Dec;42(12):643-654. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917322/>
40. [△]Elkoshi Z. Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites? *Front Immunol*. 2022 Jan 25;13:821598. <https://doi.org/10.3389/fimmu.2022.821598>
41. [△]Stoff R, Wolf Y, Boursi B. Fecal Microbiota Transplantation as a Cancer Therapeutic. *Cancer J*. 2023 Mar-Apr 01;29(2):102-108. <https://doi.org/10.1097/PP0.0000000000000651>
42. [△]Liu X, Liu M, Zhao M, Li P, Gao C, Fan X, Cai G, Lu Q, Chen X. Fecal microbiota transplantation for the management of autoimmune diseases: Potential mechanisms and challenges. *J Autoimmun*. 2023 Dec;141:103109. <https://doi.org/10.1016/j.jaut.2023.103109>
43. [△]Wang, H., Yang, F., Zhang, S. et al. Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation. *npj Parkinsons Dis*. 7, 70

(2021). <https://doi.org/10.1038/s41531-021-00213-7>

44. ^ΔAbdel-Hamed, E.F., Ibrahim, M.N., Mostafa, N.E. et al. Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections. *Gut Pathog* 13, 29 (2021). <https://doi.org/10.1186/s13099-021-00427-3>
45. ^ΔCremoni M, Allouche J, Graça D, Zorzi K, Fernandez C, Teisseyre M, et al. Low baseline IFN- γ response could predict hospitalization in COVID-19 patients. *Front Immunol*. 2022 Sep 26;13:953502. <https://doi.org/10.3389/fimmu.2022.953502>
46. ^ΔFerreira-Gomes, M., Kruglov, A., Durek, P. et al. SARS-CoV-2 in severe COVID-19 induces a TGF- β -dominate d chronic immune response that does not target itself. *Nat Commun* 12, 1961 (2021). <https://doi.org/10.1038/s41467-021-22210-3>
47. ^ΔChen W. A potential treatment of COVID-19 with TGF- β blockade. *Int J Biol Sci*. 2020 Apr 21;16(11):1954-1955. <https://doi.org/10.7150/ijbs.46891>
48. ^ΔWang XF, Wang HS, Wang H, Zhang F, Wang KF, Guo Q, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. *Cell Immunol*. 2014 May-Jun;289(1-2):42-8. <https://doi.org/10.1016/j.cellimm.2014.02.005>
49. ^ΔPallotta MT, Rossini S, Suvieri C, Coletti A, Orabona C, Macchiarulo A, et al. Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. *FEBS J*. 2022 Oct;289(20):6099-6118 <https://doi.org/10.1111/febs.16086>
50. ^ΔChen, W. IDO: more than an enzyme. *Nat Immunol* 12, 809–811 (2011). <https://doi.org/10.1038/ni.2088>
51. ^ΔYe Z, Yue L, Shi J, Shao M, Wu T. Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications. *J Cancer*. 2019 Jun 2;10(12):2771-2782. <https://doi.org/10.7150/jca.31727>
52. ^ΔChung JY, Chan MK, Li JS, Chan AS, Tang PC, Leung KT, et al. TGF- β Signaling: From Tissue Fibrosis to Tumor Microenvironment. *Int J Mol Sci*. 2021 Jul 15;22(14):7575. <https://doi.org/10.3390/ijms22147575>
53. ^ΔSri-Ngern-Ngam K, Keawvilai P, Pisitkun T, Palaga T. Upregulation of programmed cell death 1 by interferon gamma and its biological functions in human monocytes. *Biochem Biophys Rep*. 2022 Oct 17;32:101369 <https://doi.org/10.1016/j.bbrep.2022.101369>
54. ^{a, b}Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN- γ in tumor progression and regression: a review. *Biomark Res*. 2020 Sep 29;8:49. <https://doi.org/10.1186/s40364-020-00228-x>
55. ^ΔChen, Z., Han, F., Du, Y. et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. *Sig Transduct Target Ther* 8, 70 (2023). <https://doi.org/10.1038/s41392-023-01332-8>
56. ^ΔNumata Y, Akutsu N, Ishigami K, Koide H, Wagatsuma K, Motoya M, Sasaki S, Nakase H. Synergistic effect of IFN- γ and IL-1 β on PD-L1 expression in hepatocellular carcinoma. *Biochem Biophys Rep*. 2022 May 5;30:1

01270. <https://doi.org/10.1016/j.bbrep.2022.101270>

57. [△]Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, et al. Angiotensin II stimulates canonical TGF- β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. *J Mol Med (Berl)*. 2015 Mar;93(3):289–302. <https://doi.org/10.1016/j.bbrep.2022.101369>
58. [△]Pujantell M, Skenteris NT, Claussen JM, Grünhagel B, Thiele RJ, Altfeld M. Sex-dependent differences in type I IFN-induced natural killer cell activation. *Front Immunol*. 2023 Dec 15;14:1277967. <https://doi.org/10.3389/fimmu.2023.1277967>
59. [△]Castenmiller C, Keumatio-Doungtsop BC, van Ree R, de Jong EC, van Kooyk Y. Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance. *Front Immunol*. 2021 Feb 19;12:643240. <https://doi.org/10.3389/fimmu.2021.643240>
60. [△]Angioni R, Sánchez-Rodríguez R, Viola A, Molon B. TGF- β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment. *Cancers*. 2021; 13(3):401. <https://doi.org/10.3390/cancers13030401>
61. [△]Hu ZJ, Xu J, Yin JM, Li L, Hou W, Zhang LL, et al. Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. *Front Immunol*. 2020 Sep 29;11:585647. <https://doi.org/10.3389/fimmu.2020.585647>
62. [△]Frangogiannis N. Transforming growth factor- β in tissue fibrosis. *J Exp Med*. 2020 Feb 13;217(3):e20190103 <https://doi.org/10.1084/jem.20190103>
63. [△]Ong CH, Tham CL, Harith HH, Firdaus N, Israf DA. TGF- β -induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies. *Eur J Pharmacol*. 2021 Nov 15;911:174510. <https://doi.org/10.1016/j.ejphar.2021.174510>
64. [△]Cabral-Marques O, Moll G, Catar R, Preuß B, Bankamp L, Pecher AC, et al. Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. *Autoimmun Rev*. 2023 May;22(5):103310. <https://doi.org/10.1016/j.autrev.2023.103310>.
65. [△][‡]Cabral-Marques, O., Halpert, G., Schimke, L.F. et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. *Nat Commun* 13, 1220 (2022). <https://doi.org/10.1038/s41467-022-28905-5>
66. [△]Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. *J Transl Autoimmun*. 2021;4:100100. <https://doi.org/10.1016/j.jtauto.2021.100100>
67. [△][‡]Riemekasten G, Petersen F, Heidecke H. What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases. *Front Immunol*. 20 <https://doi.org/10.3389/fimm>

68. [△]Gunning, W.T., III; Stepkowski, S.M.; Kramer, P.M.; Karabin, B.L.; Grubb, B.P. Inflammatory Biomarkers in Postural Orthostatic Tachycardia Syndrome with Elevated G-Protein-Coupled Receptor Autoantibodies. *J. Clin. Med.* 2021, 10, 623. <https://doi.org/10.3390/jcm10040623>
69. [△]Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. *Brain Behav Immun.* 2016 Feb;5:2:32–39. <https://doi.org/10.1016/j.bbi.2015.09.013>
70. [△][‡]Malkova AM, Shoenfeld Y. Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic tachycardia syndrome, autoimmune diseases and autoimmune/inflammatory syndrome induced by adjuvants. *Autoimmun Rev.* 2023 Jan;22(1):103230. <https://doi.org/10.1016/j.autrev.2022.103230>
71. [△]Yadaw AS, Sahner DK, Sidky H, Afzali B, Hotaling N, Pfaff ER, et al, Preexisting Autoimmunity Is Associated With Increased Severity of Coronavirus Disease 2019: A Retrospective Cohort Study Using Data From the National COVID Cohort Collaborative (N3C), *Clinical Infectious Diseases*, Volume 77, Issue 6, 15 September 2023, Pages 816–826 <https://doi.org/10.1093/cid/ciad29>
72. [△]Klein, J., Wood, J., Jaycox, J.R. et al. Distinguishing features of long COVID identified through immune profiling. *Nature* 623, 139–148 (2023). <https://doi.org/10.1038/s41586-023-06651-y>
73. [△]Fayyaz, H., Ambreen, S., Raziq, H., & Hayyat, A. (2021). Comparison of cortisol levels in patients with vasovagal syncope and postural tachycardia syndrome. *Pakistan Journal of Medical Sciences*, 38(1). <https://doi.org/10.12669/pjms.38.1.4122>
74. [△]Lin J, Zhao H, Shen J, Jiao F, Salivary Cortisol Levels Predict Therapeutic Response to a Sleep-Promoting Method in Children with Postural Tachycardia Syndrome (2017) *The Journal of Pediatrics*. 191:91–95 <https://doi.org/10.1016/j.jpeds.2017.08.039>
75. [△]Laurin JKH, Oyewunmi OA, Garland EM, Gamboa A, Nwazue VC, Paranjape SY, et al. Adrenal gland response to adrenocorticotrophic hormone is intact in patients with postural orthostatic tachycardia syndrome. *Auton Neurosci.* 2023 Sep;248:103105. <https://doi.org/10.1016/j.autneu.2023.103105>
76. [△][‡]Hutchings CJ, Koglin M, Marshall FH (2010) Therapeutic antibodies directed at G protein-coupled receptors, *mAbs*, 2:6, 594–606, <https://doi.org/10.4161/mabs.2.6.13420>
77. [△]Hazell GG, Hindmarch CC, Pope GR, Roper JA, Lightman SL, Murphy D, et al. G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei—serpentine gateways to neuroendocrine homeost

- asis. *Front Neuroendocrinol.* 2012 Jan;33(1):45–66. <https://doi.org/10.1016/j.yfrne.2011.07.002>
78. [△]Jiang Z, Rajamanickam S, Justice NJ. Local Corticotropin-Releasing Factor Signaling in the Hypothalamic Paraventricular Nucleus. *J Neurosci.* 2018 Feb 21;38(8):1874–1890. <https://doi.org/10.1523/JNEUROSCI.1492-17.2017>
 79. ^{a, b, △}Jiang Z, Rajamanickam S, Justice NJ. CRF signaling between neurons in the paraventricular nucleus of the hypothalamus (PVN) coordinates stress responses. *Neurobiol Stress.* 2019 Aug 10;11:100192. <https://doi.org/10.1016/j.yynstr.2019.100192>.
 80. [△]Liu Q, Mak JWY, Su Q, et al Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome *Gut* 2022;71:544–552 <https://doi.org/10.1136/gutjnl-2021-325989>
 81. ^{a, b}Alenazy MF, Aljohar HI, Alruwaili AR, Daghestani MH, Alonazi MA, Labban RS, et al. Gut Microbiota Dynamics in Relation to Long-COVID-19 Syndrome: Role of Probiotics to Combat Psychiatric Complications. *Metabolites.* 2022; 12(10):912. <https://doi.org/10.3390/metabo12100912>
 82. [△]Pundir P, Kulka M. The role of G protein-coupled receptors in mast cell activation by antimicrobial peptides: is there a connection? *Immunol Cell Biol.* 2010 Aug;88(6):632–40. <https://doi.org/10.1038/icb.2010.27>
 83. [△]Paavola KJ, Sidik H, Zuchero JB, Eckart M, Talbot WS. Type IV collagen is an activating ligand for the adhesion G protein-coupled receptor GPR126. *Sci Signal.* 2014 Aug 12;7(338):ra76. <https://www.science.org/doi/10.1126/scisignal.20053473>
 84. [△]Salzer J, Ray S, Schicker K, Boehm S. Nociceptor Signaling through ion Channel Regulation via GPCRs. *International Journal of Molecular Sciences.* 2019; 20(10):2488. <https://doi.org/10.3390/ijms20102488>
 85. [△]McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro) Thrombosis in COVID-19 and Its Therapeutic Implications. *Circ Res.* 2020 Jul 31;127(4):571–587. <https://doi.org/10.1161/CIRCRESAHA.120.317447>
 86. [△]Offermanns S. Activation of platelet function through G protein-coupled receptors. *Circ Res.* 2006 Dec 8;99(12):1293–304. <https://doi.org/10.1161/01.RES.0000251742.71301.16>
 87. [△]Thakur N, Ray AP, Sharp L, Jin B, Duong A, Pour NG, et al. Anionic phospholipids control mechanisms of GPCR-G protein recognition. *Nat Commun.* 2023 Feb 13;14(1):794. <https://doi.org/10.1038/s41467-023-36425-z>
 88. [△]Chang, S.E., Feng, A., Meng, W. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. *Nat Commun* 12, 5417 (2021) <https://doi.org/10.1038/s41467-021-25509-3>
 89. [△]Natalini, J.G., Singh, S. & Segal, L.N. The dynamic lung microbiome in health and disease. *Nat Rev Microbiol* 21, 222–235 (2023). <https://doi.org/10.1038/s41579-022-00821-x>
 90. [△]Sencio V, Machado MG, Trottein F. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes. *Mucosal Immunol.* 2021 Mar;14(2):296–304. <https://doi.org/10.1038>

91. [△]Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* 2004 Jun;203(2):631-7. <https://doi.org/10.1002%2Fpath.1570>
92. [△]Yu, Z., Yang, Z., Wang, Y., Zhou, F., Li, S., Li, C., Li, L., Zhang, W., & Li, X. (2021). Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis. *Heliyon*, 7. <https://doi.org/10.1016%2Fj.heliyon.2021.e07548>
93. [△]Brown, N.A., Schrevels, S., van Dijk, P. et al. Fungal G-protein-coupled receptors: mediators of pathogenesis and targets for disease control. *Nat Microbiol* 3, 402–414 (2018). <https://doi.org/10.1038/s41564-018-0127-5>
94. [△]Chambers, PW (2023), The Candida Covid Connection: Preexisting Candida Overgrowth and Gut Dysbiosis Drives Long Covid, *J. Neuroscience and Neurological Surgery*, 13(7); DOI:10.31579/2578-8868/283 <https://doi.org/10.31579/2578-8868/283>
95. [△]Kherad Z, Yazdanpanah S, Saadat F, Pakshir K, Zomorodian K. Vitamin D3: A promising antifungal and antibiofilm agent against Candida species. *Curr Med Mycol.* 2023 Jun;9(2):17-22. <https://pubmed.ncbi.nlm.nih.gov/38375518/>
96. [△]Villa S, Hamideh M, Weinstock A, Qasim MN, Hazbun TR, Sellam A, et al. Transcriptional control of hyphal morphogenesis in Candida albicans. *FEMS Yeast Res.* 2020 Feb 1;20(1):foaa005. <https://doi.org/10.1093/femsyr/foaa005>
97. [△]Atriwal T, Azeem K, Husain FM, Hussain A, Khan MN, Alajmi MF, et al. Mechanistic Understanding of Candida albicans Biofilm Formation and Approaches for Its Inhibition. *Front Microbiol.* 2021 Apr 30;12:638609. <https://doi.org/10.3389/fmicb.2021.638609>
98. [△]Kumar, D., Kumar, A. Molecular Determinants Involved in Candida albicans Biofilm Formation and Regulation. *Mol Biotechnol* (2023). <https://doi.org/10.1007/s12033-023-00796-x>
99. [△]Kumwenda P, Cottier F, Hendry AC, Kneafsey D, Keenan B, Gallagher H, et al. Estrogen promotes innate immune evasion of Candida albicans through inactivation of the alternative complement system. *Cell Rep.* 2022 Jan 4;38(1):110183. <https://doi.org/10.1016/j.celrep.2021.110183>
100. [△]Ahmed N, Mahmood MS, Ullah MA, Araf Y, Rahaman TI, Moin AT, et al. COVID-19-Associated Candidiasis: Possible Patho-Mechanism, Predisposing Factors, and Prevention Strategies. *Curr Microbiol.* 2022 Mar 14;79(5):127. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918595/>
101. [△]Abdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK. SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. *Am J Physiol Lung Cell Mol Physiol.* 2021 Mar 1;

320(3):L430–L435. <https://pubmed.ncbi.nlm.nih.gov/33434105/>

102. ^ΔAbdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK. SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. *Am J Physiol Lung Cell Mol Physiol*. 2021 Mar 1; 320(3):L430–L435. <https://doi.org/10.1152/ajplung.00499.2020>
103. ^ΔElkazzaz M, Ahmed A, Abo-Amer YE-E, Hydera T, Haikal A, Razek DNAE, et al. In Silico Discovery of GPCRs and GnRHRs as Novel Binding Receptors of SARS-CoV-2 Spike Protein Could Explain Neuroendocrine Disorders in COVID-19. *Vaccines*. 2022; 10(9):1500. <https://doi.org/10.3390/vaccines10091500>
104. ^ΔCâmara AB, Brandão IA. The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis. *Curr Med Chem*. 2021 Oct 27;28(34):7157–7184. <https://doi.org/10.2174/0929867328666210405113253>
105. ^ΔHohberger B, Harrer T, Mardin C, Kruse F, Hoffmanns J, Rogge L, et al. Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection. *Front Med (Lausanne)*. 2021 Nov 18;8:754667. <https://doi.org/10.3389/fmed.2021.754667>
106. ^ΔZhang Q, Friedman PA. Receptor-Loaded Virion Endangers GPCR Signaling: Mechanistic Exploration of SARS-CoV-2 Infections and Pharmacological Implications. *Int J Mol Sci*. 2021 Oct 11;22(20):10963. <https://doi.org/10.3390/ijms222010963>
107. ^ΔWallukat G, Wernike K, Bachamanda Somesh D, Mettenleiter TC, Müller J. Animals Experimentally Infected with SARS-CoV-2 Generate Functional Autoantibodies against G-Protein-Coupled Receptors. *Biomedicines*. 2023; 11(10):2668. <https://doi.org/10.3390/biomedicines11102668>
108. ^ΔSyed, U, Subramanian, A, Wraith, D.C. et al. Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care. *BMC Med* 21, 363 (2023). <https://doi.org/10.1186/s12916-023-03049-5>
109. ^ΔMorshed SA, Ma R, Latif R, Davies TF. Biased signaling by thyroid-stimulating hormone receptor-specific antibodies determines thyrocyte survival in autoimmunity. *Sci Signal*. 2018 Jan 23;11(514):eaah4120. <https://doi.org/10.1126/scisignal.aah4120>
110. ^ΔQiu K, Li K, Zeng T, Liao Y, Min J, Zhang N, Peng M, Kong W, Chen LL. Integrative Analyses of Genes Associated with Hashimoto's Thyroiditis. *J Immunol Res*. 2021 Aug 28;2021:8263829. <https://doi.org/10.1155/2021/8263829>
111. ^ΔBanerjee P, Bhagavatula S, Sood A, Midha V, Thelma BK, Senapati S. Association study identified biologically relevant receptor genes with synergistic functions in celiac disease. *Sci Rep*. 2019 Sep 25;9(1):13811. <https://doi.org/10.1038/s41598-019-50120-4>

112. [△]Sumida H. Recent advances in roles of G-protein coupled receptors in intestinal intraepithelial lymphocytes. *Biosci Microbiota Food Health*. 2020;39(3):77-82. <https://doi.org/10.12938/bmfh.2019-053>
113. [△]Feng, Z., Sun, R., Cong, Y. et al. Critical roles of G protein-coupled receptors in regulating intestinal homeostasis and inflammatory bowel disease. *Mucosal Immunol* 15, 819–828 (2022). <https://doi.org/10.1038/s41385-022-00538-3>
114. [△]Xu, B., Pirskanen, R., Lefvert, AK. Antibodies against β 1 and β 2 adrenergic receptors in myasthenia gravis 1998;91(1-2):82-88 [https://doi.org/10.1016/S0165-5728\(98\)00159-3](https://doi.org/10.1016/S0165-5728(98)00159-3)
115. [△]Engevik AC, Kaji I, Goldenring JR. The Physiology of the Gastric Parietal Cell. *Physiol Rev*. 2020 Apr 1;100(2):573–602. <https://doi.org/10.1152/physrev.00016.2019>
116. [△]Buerger C. Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target. *Front Immunol*. 2018 Nov 30;9:2786. <https://doi.org/10.3389/fimmu.2018.02786>
117. [△]Zhao J, Wei K, Jiang P, Chang C, Xu L, Xu L, et al. G-Protein-Coupled Receptors in Rheumatoid Arthritis: Recent Insights into Mechanisms and Functional Roles. *Front Immunol*. 2022 Jul 8;13:907733. <https://doi.org/10.3389/fimmu.2022.907733>
118. [△]Jin M, Hwang SM, Davies AJ, Shin Y, Bae JS, Lee JH, et al. Autoantibodies in primary Sjögren's syndrome patients induce internalization of muscarinic type 3 receptors. *Biochim Biophys Acta*. 2012 Feb;1822(2):161-7. <https://doi.org/10.1016/j.bbdis.2011.11.012>
119. [△]Cabral-Marques, O., Marques, A., Giil, L.M. et al. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. *Nat Commun* 9, 5224 (2018). <https://doi.org/10.1038/s41467-018-07598-9>
120. [△]Zhang J, Xiao Y, Hu J, Liu S, Zhou Z, Xie L. Lipid metabolism in type 1 diabetes mellitus: Pathogenetic and therapeutic implications. *Front Immunol*. 2022 Oct 6;13:999108. <https://doi.org/10.3389/fimmu.2022.999108>
121. [△]Carlson JA, Linette GP, Aplin A, Ng B, Slominski A. Melanocyte receptors: clinical implications and therapeutic relevance. *Dermatol Clin*. 2007 Oct;25(4):541-57, viii-ix. <https://doi.org/10.1016%2Fj.det.2007.06.005>
122. [△]Unutmaz D, KewalRamani VN, Littman DR. G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models. *Semin Immunol*. 1998 Jun;10(3):225–36. <https://doi.org/10.1006/smim.1998.0134>
123. [△]Chow, D, Nakamoto, BK, Sullivan, K, Sletten, DM, Fujii, S, Umekawa, S, et al, Symptoms of Autonomic Dysfunction in Human Immunodeficiency Virus, *Open Forum Infectious Diseases*, Volume 2, Issue 3, Summer 2015, ofv103, <https://doi.org/10.1093/ofid/>

124. [△]Takahashi T, Flanagan KL. Sex differences in immune responses that underlie COVID-19 disease outcomes *Nature* 588, 315–320 (2020). <https://doi.org/10.1038/nri.2016.90>
125. [△]Pujantell M, Altfeld M. Consequences of sex differences in Type I IFN responses for the regulation of antiviral immunity *Front Immunol.* 2022 Sep 16;13:986840 <https://doi.org/10.3389/fimmu.2022.986840>
126. [△]Delsing, C.E., Gresnigt, M.S., Leentjens, J. et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. *BMC Infect Dis* 14, 166 (2014). <https://doi.org/10.1186/1471-2334-14-166>
127. [△]Gozalbo D, Gil ML. IFN-gamma in *Candida albicans* infections. *Front Biosci (Landmark Ed)*. 2009 Jan 1;14(5):1970–8. <https://doi.org/10.2741/3356>
128. [△]Li J, Li Y, Wang Z, Liu N, He L, Zhang H. Increased risk of new-onset diabetes in patients with COVID-19: a systematic review and meta-analysis. *Front Public Health.* 2023 May 25;11:1170156. <https://doi.org/10.3389/fpubh.2023.1170156>
129. [△]Fridlyand LE, Philipson LH. Pancreatic Beta Cell G-Protein Coupled Receptors and Second Messenger Interactions: A Systems Biology Computational Analysis. *PLoS One.* 2016 May 3;11(5):e0152869. <https://doi.org/10.1371/journal.pone.0152869>.
130. [△]Miranda M, Avila I, Esparza J, Shwartz Y, Hsu YC, Berdeaux R, et al. Defining a Role for G-Protein Coupled Receptor/cAMP/CRE-Binding Protein Signaling in Hair Follicle Stem Cell Activation. *J Invest Dermatol.* 2022 Jan;142(1):53–64.e3. <https://doi.org/10.1016/j.jid.2021.05.031>
131. [△]Krejner, A., Bruhs, A., Mrowietz, U. et al. Decreased expression of G-protein-coupled receptors GPR43 and GPR109a in psoriatic skin can be restored by topical application of sodium butyrate. *Arch Dermatol Res* 310, 751–758 (2018) <https://doi.org/10.1007/s00403-018-1865-1>
132. [△]Yang, L., Zhang, L., Du, Q. et al. Exploring the molecular mechanism underlying the psoriasis and T2D by using microarray data analysis. *Sci Rep* 13, 19313 (2023). <https://doi.org/10.1038/s41598-023-46795-5>
133. [△]Pietrzak A, Grywalska E, Socha M, Roliński J, Franciszewicz-Pietrzak K, Rudnicka L, et al. Prevalence and Possible Role of *Candida* Species in Patients with Psoriasis: A Systematic Review and Meta-Analysis. *Mediators Inflamm.* 2018 May 6;2018:9602362. <https://doi.org/10.1155/2018/9602362>
134. [△]Carlson JA, Linette GP, Aplin A, Ng B, Slominski A. Melanocyte receptors: clinical implications and therapeutic relevance. *Dermatol Clin.* 2007 Oct;25(4):541–57, viii–ix. <https://doi.org/10.1016/j.det.2007.06.005>
135. [△]El-Arif G, Khazaal S, Farhat A, Harb J, Annweiler C, Wu Y, et al. Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases. *Molecules.* 2022 Mar 22;27(7):2048. <https://doi.org/10.3390/molecules27072048>

136. [△]Bousoik E, Montazeri Aliabadi H. Do We Know Jack About JAK? A Closer Look at JAK/STAT Signaling Pathway. *Front Oncol.* 2018 Jul 31;8:287. <https://doi.org/10.3389/fonc.2018.00287>
137. [△]Chaudhary PK, Kim S. An Insight into GPCR and G-Proteins as Cancer Drivers. *Cells.* 2021 Nov 24;10(12):3288. <https://doi.org/10.3390/cells10123288>
138. [△]Herhaus B, Thesing G, Conrad R, Petrowski K. Alterations in heart rate variability and pro-inflammatory cytokine TNF-alpha in individuals with panic disorder. *Psychiatry Res.* 2023 Apr;322:115107 <https://doi.org/10.1016/j.psychres.2023.115107>
139. [△]Thanou, A., Stavrakis, S., Dyer, J.W. et al. Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. *Arthritis Res Ther* 18, 197 (2016). <https://doi.org/10.1186/s13075-016-1087-x>
140. [△]Jones DR, Smyth JM, Engeland CG, Sliwinski MJ, Russell MA, Sin NL, et al. Affect variability and inflammatory markers in midlife adults. *Health Psychol.* 2020 Aug;39(8):655–666. <https://doi.org/10.1016%2Fj.bbih.2021.100273>
141. [△]Wang, X., Lin, Y. Tumor necrosis factor and cancer, buddies or foes? *Acta Pharmacol Sin* 29, 1275–1288 (2008). <https://doi.org/10.1111%2Fj.1745-7254.2008.00889.x>
142. [△]Rébé C, Ghiringhelli F. Interleukin-1 β and Cancer. *Cancers.* 2020; 12(7):1791. <https://doi.org/10.3390/cancers12071791>
143. [△]Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. *Tumour Biol.* 2016 Sep;37(9):11553–11572. <https://doi.org/10.1007/s13277-016-5098-7>
144. [△]Williams DP, Koenig J, Carnevali L, Sgoifo A, Jarczok MN, Sternberg EM, Thayer JF. Heart rate variability and inflammation: A meta-analysis of human studies. *Brain Behav Immun.* 2019 Aug;80:219–226. <https://doi.org/10.1016/j.bbi.2019.03.009>
145. [△]Cooper TM, McKinley PS, Seeman TE, Choo TH, Lee S, Sloan RP. Heart rate variability predicts levels of inflammatory markers: Evidence for the vagal anti-inflammatory pathway. *Brain Behav Immun.* 2015 Oct;49:94–100 <https://doi.org/10.1016%2Fj.bbi.2014.12.017>
146. [△]Steffen PR, Bartlett D, Channell RM, Jackman K, Cressman M, Bills J, Pescatello M. Integrating Breathing Techniques Into Psychotherapy to Improve HRV: Which Approach Is Best? *Front Psychol.* 2021 Feb 15;12:624254 <https://doi.org/10.3389/fpsyg.2021.624254>
147. [△]Hartmann R, Schmidt FM, Sander C, Hegerl U. Heart Rate Variability as Indicator of Clinical State in Depression. *Front Psychiatry.* 2019 Jan 17;9:735. <https://doi.org/10.3389%2Ffpsyg.2018.00735>
148. [△][‡]Koch C, Wilhelm M, Salzmann S, Rief W, Euteneuer F. A meta-analysis of heart rate variability in major depression. *Psychological Medicine.* 2019;49(12):1948–1957. <https://doi.org/10.1017/s0033291719001351>

149. [△]Arakaki X, Arechavala RJ, Choy EH, Bautista J, Bliss B, Molloy C, et al. The connection between heart rate variability (HRV), neurological health, and cognition: A literature review. *Front Neurosci.* 2023 Mar 1;17:1055445 <https://doi.org/10.3389/fnins.2023.1055445>
150. [△]Liu KY, Elliott T, Knowles M, Howard R. Heart rate variability in relation to cognition and behavior in neurodegenerative diseases: A systematic review and meta-analysis. *Ageing Res Rev.* 2022 Jan;73:101539. <https://doi.org/10.1016/j.arr.2021.101539>
151. [△]Benjamin BR, Valstad M, Elvsåshagen T, Jönsson EG, Moberget T, Winterton A, et al. Heart rate variability is associated with disease severity in psychosis spectrum disorders. *Prog Neuropsychopharmacol Biol Psychiatry.* 2021 Dec 20;111:110108. <https://doi.org/10.1016/j.pnpbp.2020.110108>
152. [△]Kloter E, Barrueto K, Klein SD, Scholkmann F, Wolf U. Heart Rate Variability as a Prognostic Factor for Cancer Survival – A Systematic Review. *Front Physiol.* 2018 May 29;9:623. <https://doi.org/10.3389/fphys.2018.00623>
153. [△]Guo, Y, Koshy, S, Hui, D, Palmer, JL, Shin, K, Bozkurt, Mehtap, et al. Prognostic Value of Heart Rate Variability in Patients With Cancer. *Journal of Clinical Neurophysiology* 32(6):p 516–520, December 2015 <https://doi.org/10.1097%2FWNP.0000000000000210>
154. [△]Kubota Y, Chen LY, Whitsel EA, Folsom AR. Heart rate variability and lifetime risk of cardiovascular disease: the Atherosclerosis Risk in Communities Study. *Ann Epidemiol.* 2017 Oct;27(10):619–625.e2. <https://doi.org/10.1016%2Fj.annepidem.2017.08.024>
155. [△]Musialik-Łydka A, Sredniawa B, Pasyk S. Heart rate variability in heart failure. *Kardiol Pol.* 2003 Jan;58(1):10–6. <https://pubmed.ncbi.nlm.nih.gov/14502297/>
156. [△]Lees T, Shad-Kaneez F, Simpson AM, Nassif NT, Lin Y, Lal S. Heart Rate Variability as a Biomarker for Predicting Stroke, Post-stroke Complications and Functionality. *Biomark Insights.* 2018 Jul 18;13:1177271918786931. <https://doi.org/10.1177%2F1177271918786931>
157. [△]Buitrago-Ricarte N, Cintra F, Silva GS. Heart rate variability as an autonomic biomarker in ischemic stroke. *Arq Neuropsiquiatr.* 2020 Nov;78(11):724–732. <https://doi.org/10.1590/0004-282x20200087>
158. [△]Benichou T, Pereira B, Mermillod M, Tauveron I, Pfabigan D, Maqdasy S, et al. Heart rate variability in type 2 diabetes mellitus: A systematic review and meta-analysis. *PLoS One.* 2018 Apr 2;13(4):e0195166. <https://doi.org/10.1371%2Fjournal.pone.0195166>
159. [△]Schroeder, EB, Chambless, LE, Liao, D, Prineas, RJ, Evans, GW, Rosamond, WD, et al. Diabetes, Glucose, Insulin, and Heart Rate Variability: The Atherosclerosis Risk in Communities (ARIC) study. *Diabetes Care* 1 March 2005; 28 (3): 668–674 <https://doi.org/10.2337/diacare.28.3.668>

160. [△]Hirten RP, Danieleto M, Tomalin L, Choi KH, Zweig M, Golden E, et al. Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study J Med Internet Res 2021;23(2):e26107 <https://doi.org/10.2196/26107>
161. [△]da Silva, A.L.G., Vieira, L.d.P., Dias, L.S. et al. Impact of long COVID on the heart rate variability at rest and during deep breathing maneuver. Sci Rep 13, 22695 (2023). <https://doi.org/10.1038/s41598-023-50276-0>
162. [△]Suh H-W, Kwon C-Y, Lee B. Long-Term Impact of COVID-19 on Heart Rate Variability: A Systematic Review of Observational Studies. Healthcare. 2023; 11(8):1095. <https://doi.org/10.3390/healthcare11081095>
163. [△]Mooren, F.C., Böckelmann, I., Waranski, M. et al. Autonomic dysregulation in long-term patients suffering from Post-COVID-19 Syndrome assessed by heart rate variability. Sci Rep 13, 15814 (2023). <https://doi.org/10.1038/s41598-023-42615-y>
164. [△]Garis, G., Haupts, M., Duning, T. et al. Heart rate variability and fatigue in MS: two parallel pathways representing disseminated inflammatory processes. Neurol Sci 44, 83–98 <https://doi.org/10.1007/s10072-022-06385-1>
165. [△]Novikova DS, Popkova TV, Panafidina TA, Il'ina AE, Kliukvina NG, Markelova EI, et al. Clinical significance of heart rate variability in patients with systemic lupus erythematosus. Ter Arkh. 2008;80(9):68-72. <https://pubmed.ncbi.nlm.nih.gov/19555041/>
166. [△]Ingegnoli F, Buoli M, Antonucci F, Coletto LA, Esposito CM, Caporali R. The Link Between Autonomic Nervous System and Rheumatoid Arthritis: From Bench to Bedside. Front Med (Lausanne). 2020 Dec 7;7:589079. <https://doi.org/10.3389/fmed.2020.589079>
167. ^{a, b}Windham BG, Fumagalli S, Ble A, et al. The Relationship between Heart Rate Variability and Adiposity Differs for Central and Overall Adiposity. Journal of Obesity. 2012;2012:149516 <https://doi.org/10.1155/2012/149516>
168. ^{a, b}Farah BQ, Prado WL, Tenório TR, Ritti-Dias RM. Heart rate variability and its relationship with central and general obesity in obese normotensive adolescents. Einstein (Sao Paulo). 2013 Jul-Sep;11(3):285-90. <https://doi.org/10.1590/s1679-45082013000300005>
169. [△]Yadav RL, Yadav PK, Yadav LK, Agrawal K, Sah SK, Islam MN. Association between obesity and heart rate variability indices: an intuition toward cardiac autonomic alteration – a risk of CVD. Diabetes Metab Syndr Obes. 2017 Feb 17;10:57-64. <https://doi.org/10.2147/dmso.s123935>
170. [△]Rastović M, Srdić-Galić B, Barak O, Stokić E. Association between anthropometric measures of regional fat mass and heart rate variability in obese women. Nutr Diet. 2017 Feb;74(1):51-60. <https://doi.org/10.1111/1747-0080.12280>

171. [△]Rose, S, Bennuri, S.C., Davis, J.E. et al. Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism. *Transl Psychiatry* 8, 42 (2018). <https://doi.org/10.1038/s41398-017-0089-z>
172. [△]Rode, J, Yang, L, König, J, Hutchinson, AN, Wall, R, Venizelos, N, et al. Butyrate Rescues Oxidative Stress-Induced Transport Deficits of Tryptophan: Potential Implication in Affective or Gut-Brain Axis Disorders. *Neuropsychobiology* 27 May 2021; 80 (3): 253–263 <https://doi.org/10.1159/000510886>
173. [△]Gao K, Mu CL, Farzi A, Zhu WY. Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain. *Adv Nutr*. 2020 May 1;11(3):709–723. <https://doi.org/10.1093/advances/nmz127>
174. [△]Siddiqui MT, Cresci GAM. The Immunomodulatory Functions of Butyrate. *J Inflamm Res*. 2021 Nov 18;14:6025–6041. <https://doi.org/10.2147/JIR.S300989>
175. [△]Tsubokawa M, Nishimura M, Mikami T, Ishida M, Hisada T, Tamada Y. Association of Gut Microbial Genes with Heart Rate Variability in the General Japanese Population: The Iwaki Cross-Sectional Research Study. *Metabolites*. 2022; 12(8):730. <https://doi.org/10.3390/metabo12080730>
176. [△]Domuschiev, I, The relationship between Heart Rate Variability (HRV) and gut microbiota Mar 2023 *ResearchGate* <https://www.researchgate.net/publication/369356948>
177. [△]Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, et al. Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. *Nutrients*. 2023; 15(9):2211. <https://doi.org/10.3390/nu1509221>
178. [△]Coppola S, Avagliano C, Calignano A, Berni Canani R. The Protective Role of Butyrate against Obesity and Obesity-Related Diseases. *Molecules*. 2021; 26(3):682. <https://doi.org/10.3390/molecules26030682>
179. [△]Peng K, Dong W, Luo T, Tang H, Zhu W, Huang Y, et al. Butyrate and obesity: Current research status and future prospect. *Front Endocrinol (Lausanne)*. 2023 Feb 24;14:1098881. <https://doi.org/10.3389/fendo.2023.1098881>
180. [△]van Deuren T, Blaak EE, Canfora EE. Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. *Obes Rev*. 2022 Oct;23(10):e13498 <https://doi.org/10.1111/obr.13498>
181. [△]Ridger, C. Acetate promotes obesity via a gut–brain– β -cell axis. *Nat Rev Endocrinol* 12, 436 (2016). <https://doi.org/10.1038/nrendo.2016.93>
182. [△]Schug, Z, Vande Voorde, J, Gottlieb, E. The metabolic fate of acetate in cancer. *Nat Rev Cancer* 16, 708–717 (2016). <https://doi.org/10.1038/nrc.2016.8>
183. [△]Baothman, O.A., Zamzami, M.A., Taher, I. et al. The role of Gut Microbiota in the development of obesity and Diabetes. *Lipids Health Dis* 15, 108 (2016). <https://doi.org/10.1186/s12944-016-0278-4>

184. ^aMa Y, Chen C. Prebiotic Functions of Mannose Oligosaccharides Revealed by Microbiomic and Metabolomic Analyses of Intestinal Digesta (P20–017-19). *Curr Dev Nutr*. 2019 Jun 13;3(Suppl 1):nzz040.P20–017-19. <https://doi.org/10.1093/cdn/nzz040.P20–017-19>
185. ^aDong, L., Xie, J., Wang, Y. et al. Mannose ameliorates experimental colitis by protecting intestinal barrier integrity. *Nat Commun* 13, 4804 (2022). <https://doi.org/10.1038/s41467-022-32505-8>
186. ^ΔZhang W, Cheng H, Gui Y, Zhan Q, Li S, Qiao W, et al. Mannose Treatment: A Promising Novel Strategy to Suppress Inflammation. *Front Immunol*. 2021 Sep 27;12:756920. <https://doi.org/10.3389/fimmu.2021.756920>
187. ^ΔSharma V, Smolin J, Nayak J, Ayala JE, Scott DA, Peterson SN, et al. Mannose Alters Gut Microbiome, Prevents Diet-Induced Obesity, and Improves Host Metabolism. *Cell Rep*. 2018 Sep 18;24(12):3087–3098. <https://doi.org/10.1016/j.celrep.2018.08.064>
188. ^ΔHaensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. *Psychoneuroendocrinology*. 2008 Nov;33(10):1305–12. <https://doi.org/10.1016/j.psyneuen.2008.08.007>
189. ^ΔFerreira, I, Snijder, MB, Twisk, JWR, van Mechelen, W, Kemper, HCG, Seidell, JC, et al. Central Fat Mass Versus Peripheral Fat and Lean Mass: Opposite (Adverse Versus Favorable) Associations with Arterial Stiffness? The Amsterdam Growth and Health Longitudinal Study, *The Journal of Clinical Endocrinology & Metabolism*, 89(6):6, 1 June 2004, Pages 2632–2639 <https://doi.org/10.1210/jc.2003-031619>
190. ^ΔCabral M, Bangdiwala SI, Severo M, Guimarães JT, Nogueira L, Ramos E. Central and peripheral body fat distribution: Different associations with low-grade inflammation in young adults? *Nutr Metab Cardiovasc Dis*. 2019 Sep;29(9):931–938. <https://doi.org/10.1016/j.numecd.2019.05.066>
191. ^ΔXiao P, Hu Z, Lang J, Pan T, Mertens RT, Zhang H, et al. Mannose metabolism normalizes gut homeostasis by blocking the TNF- α -mediated proinflammatory circuit. *Cell Mol Immunol*. 2023 Feb;20(2):119–130. <https://doi.org/10.1038/s41423-022-00955-1>
192. ^ΔTorretta S, Scagliola A, Ricci L, Mainini F, Di Marco S, Cuccovillo I, et al. D-mannose suppresses macrophage IL-1 β production. *Nat Commun*. 2020 Dec 11;11(1):6343. <https://doi.org/10.1038/s41467-020-20164-6>
193. ^ΔGuo L, Hou Y, Song L, Zhu S, Lin F, Bai Y. D-Mannose Enhanced Immunomodulation of Periodontal Ligament Stem Cells via Inhibiting IL-6 Secretion. *Stem Cells Int*. 2018 Sep 9;2018:7168231. <https://doi.org/10.1155/2018/7168231>
194. ^ΔLiu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor- α (TNF- α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. *Ann Palliat Med*. 2021 Dec;10(12):12759–12766. <https://doi.org/10.21037/apm-21-3471>

195. [△]Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. *Br J Cancer*. 2002 May 6;86(9):1396–400. <https://doi.org/10.1038/sj.bjc.6600257>
196. [△]Weber, B.N., Giles, J.T. & Liao, K.P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. *Nat Rev Rheumatol* 19, 417–428 (2023). <https://doi.org/10.1038/s41584-023-00969-7>
197. [△]Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. *J Cereb Blood Flow Metab*. 2012 Sep;32(9):1677–98. <https://doi.org/10.1038/sj.cbfm.2012.88>
198. [△]Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications. *International Journal of Molecular Sciences*. 2020; 21(10):3570. <https://doi.org/10.3390/ijms21103570>
199. [△]Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF- α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. *Cytokine*. 2016 Oct;86:100–109. <https://doi.org/10.1016/j.cyt.2016.06.028>
200. [△]Ishijima T, Nakajima K. Inflammatory cytokines TNF α , IL-1 β , and IL-6 are induced in endotoxin-stimulated microglia through different signaling cascades. *Sci Prog*. 2021 Oct;104(4):368504211054985. <https://doi.org/10.1177/00368504211054985>
201. [△]Möller, B., Villiger, P.M. Inhibition of IL-1, IL-6, and TNF- α in immune-mediated inflammatory diseases. *Springer Semin Immun* 27, 391–408 (2006) <https://doi.org/10.1007/s00281-006-0012-9>
202. [△]Mikos H, Mikos M, Rabska-Pietrzak B, Niedziela M. The clinical role of serum concentrations of selected cytokines: IL-1 β , TNF- α and IL-6 in diagnosis of autoimmune thyroid disease (AITD) in children. *Autoimmunity*. 2014 Nov;47(7):466–72. <https://doi.org/10.3109/08916934.2014.914175>
203. [△]Dhanalakshmi, M., Sruthi, D., Jinuraj, K.R. et al. Mannose: a potential saccharide candidate in disease management. *Med Chem Res* 32, 391–408 (2023). <https://doi.org/10.1007/s00044-023-03015-z>
204. [△]Nan F, Sun Y, Liang H, Zhou J, Ma X, Zhang D. Mannose: A Sweet Option in the Treatment of Cancer and Inflammation. *Front Pharmacol*. 2022 May 13;13:877543. <https://doi.org/10.3389/fphar.2022.877543>
205. [△]Zhang J, Jiang N, Ping J, Xu L. TGF- β 1-induced autophagy activates hepatic stellate cells via the ERK and JNK signaling pathways. *Int J Mol Med*. 2021 Jan;47(1):256–266. <https://doi.org/10.3892/ijmm.2020.4778>
206. [△]Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu J, et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. *Cancer Commun (Lond)*. 2023 Jan;43(1):3–41. <https://doi.org/10.1002/cac2.12392>

207. [△]Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. *Neoplasia*. 2004 Sep-Oct;6(5):603-10. <https://doi.org/10.1593/neo.04241>
208. [△]Xu J, Liu X, Jiang Y, Chu L, Hao H, Liua Z, Verfaillie C, Zweier J, Gupta K, Liu Z. MAPK/ERK signalling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell. *J Cell Mol Med*. 2008 Dec;12(6A):2395-406. <https://doi.org/10.1111/j.1582-4934.2008.00266.x>
209. [△]Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X, et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. *Proc Natl Acad Sci U S A*. 2022 Feb 22;119(8):e2114851119. <https://doi.org/10.1073/pnas.2114851119>
210. [△]Rha, MS., Shin, EC. Activation or exhaustion of CD8+ T cells in patients with COVID-19. *Cell Mol Immunol* 18, 2325–2333 (2021). <https://doi.org/10.1038/s41423-021-00750-4>
211. [△]Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, et al. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. *Mol Oncol*. 2022 Jun;16(11):2117-2134. [<https://doi.org/10.1002/1878-0261.13146>]
212. [△]Young HA, Benton D. Heart-rate variability: a biomarker to study the influence of nutrition on physiological and psychological health? *Behav Pharmacol*. 2018 Apr;29(2 and 3-Spec Issue):140-151. <https://doi.org/10.1097/FBP.0000000000000383>
213. [△]Karzon R, Jackson A, Lloyd I, Hall A, Lee L. The Role of Nutraceuticals in the Prevention and/or Treatment of COVID-19: An Umbrella Review. *CANDJ [Internet]*. 2023 Dec. 28 [cited 2024 Feb. 6];30(4):66-80 <https://candjournal.ca/index.php/candj/article/view/165>
214. [△]Souza PBD, de Araujo Borba L, Castro de Jesus L, Valverde AP, Gil-Mohapel J, Rodrigues ALS. Major Depressive Disorder and Gut Microbiota: Role of Physical Exercise. *International Journal of Molecular Sciences*. 2023; 24(23):16870. <https://doi.org/10.3390/ijms242316870>
215. [△]Reginato E, Azzolina D, Folino F, Valentini R, Bendinelli C, Gafare CE, et al. Dietary and Lifestyle Patterns are Associated with Heart Rate Variability. *J Clin Med*. 2020 Apr 14;9(4):1121. <https://doi.org/10.3390/jcm9041121>
216. [△]Hernández-Vicente A, Hernando D, Santos-Lozano A, Rodríguez-Romo G, Vicente-Rodríguez G, Pueyo E, et al. Heart Rate Variability and Exceptional Longevity. *Front Physiol*. 2020 Sep 17;11:566399. <https://doi.org/10.3389/fphys.2020.566399>

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.